Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Glaukos (NYSE:GKOS - Get Free Report) had its price objective lifted by equities researchers at Stifel Nicolaus from $153.00 to $175.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the medical instruments supplier's stock. Stifel Nicolaus' price objective would suggest a potential upside of 16.71% from the stock's current price.

Several other research analysts have also commented on the company. Stephens raised Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. UBS Group initiated coverage on shares of Glaukos in a research note on Friday, December 6th. They set a "buy" rating and a $182.00 price target for the company. Wells Fargo & Company lifted their price objective on shares of Glaukos from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Truist Financial increased their target price on shares of Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. Finally, StockNews.com upgraded Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Glaukos has an average rating of "Moderate Buy" and a consensus target price of $147.75.

Glaukos Stock Up 0.3 %

Shares of GKOS stock traded up $0.43 during trading hours on Tuesday, reaching $149.94. 768,835 shares of the stock were exchanged, compared to its average volume of 574,671. The business's fifty day moving average is $140.52 and its two-hundred day moving average is $129.79. The firm has a market capitalization of $8.27 billion, a P/E ratio of -49.65 and a beta of 1.03. Glaukos has a 12-month low of $74.75 and a 12-month high of $153.50. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company's revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.50) EPS. As a group, research analysts expect that Glaukos will post -1.89 EPS for the current fiscal year.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the sale, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,603 shares of company stock valued at $2,605,678 in the last ninety days. Corporate insiders own 6.40% of the company's stock.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently made changes to their positions in the business. Values First Advisors Inc. purchased a new stake in shares of Glaukos during the 3rd quarter worth about $25,000. Harvest Fund Management Co. Ltd grew its stake in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after buying an additional 860 shares during the period. KBC Group NV increased its position in shares of Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after acquiring an additional 201 shares in the last quarter. EWA LLC purchased a new position in shares of Glaukos in the 3rd quarter valued at $209,000. Finally, Procyon Advisors LLC purchased a new position in shares of Glaukos in the 3rd quarter valued at $210,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.